Jacobio Pharmaceuticals Group Co., Ltd. (HKG:1167)
7.05
-0.09 (-1.26%)
Apr 29, 2026, 4:08 PM HKT
HKG:1167 Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2018 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2018 |
| Cash & Equivalents | 973.65 | 1,175 | 1,148 | 1,299 | 1,538 | Upgrade
|
| Trading Asset Securities | 160.03 | - | - | - | - | Upgrade
|
| Cash & Short-Term Investments | 1,134 | 1,175 | 1,148 | 1,299 | 1,538 | Upgrade
|
| Cash Growth | -3.48% | 2.33% | -11.62% | -15.54% | -5.52% | Upgrade
|
| Accounts Receivable | 8.83 | 7.68 | 9.34 | 15.03 | 64.92 | Upgrade
|
| Other Receivables | 6.31 | 0.85 | 3.46 | 25.03 | 32.68 | Upgrade
|
| Receivables | 15.14 | 8.53 | 12.8 | 40.06 | 97.59 | Upgrade
|
| Inventory | 4.65 | 3.89 | 6.2 | - | - | Upgrade
|
| Other Current Assets | 0.32 | 1.66 | 1.57 | - | 4.55 | Upgrade
|
| Total Current Assets | 1,154 | 1,189 | 1,168 | 1,339 | 1,640 | Upgrade
|
| Property, Plant & Equipment | 129.89 | 151.49 | 219.6 | 205.23 | 41.77 | Upgrade
|
| Long-Term Investments | 17.86 | 18.16 | 68.19 | 25.42 | 16.23 | Upgrade
|
| Other Intangible Assets | 0.85 | 0.84 | 1.37 | 1.02 | 1.55 | Upgrade
|
| Long-Term Accounts Receivable | - | 0.06 | 2.91 | - | - | Upgrade
|
| Other Long-Term Assets | 1.94 | - | - | 4.23 | 22.56 | Upgrade
|
| Total Assets | 1,304 | 1,359 | 1,460 | 1,575 | 1,722 | Upgrade
|
| Accounts Payable | 43.52 | 117.96 | 81.19 | 96.55 | 51.05 | Upgrade
|
| Accrued Expenses | 13.83 | 7.56 | 17.96 | 25.4 | 19.15 | Upgrade
|
| Short-Term Debt | - | - | 73.62 | - | - | Upgrade
|
| Current Portion of Long-Term Debt | 5.64 | 56.06 | - | - | - | Upgrade
|
| Current Portion of Leases | 9.79 | 9.9 | 14.33 | 13.13 | 4.92 | Upgrade
|
| Current Income Taxes Payable | 1.73 | 1.04 | 1.94 | 2.35 | 1.97 | Upgrade
|
| Other Current Liabilities | 151.8 | 50.33 | 16.1 | 18.42 | 3.75 | Upgrade
|
| Total Current Liabilities | 226.29 | 242.85 | 205.13 | 155.85 | 80.83 | Upgrade
|
| Long-Term Debt | 89.12 | 16 | - | - | - | Upgrade
|
| Long-Term Leases | 60.62 | 70.12 | 121.97 | 134.66 | 1.89 | Upgrade
|
| Long-Term Unearned Revenue | 0.37 | 0.78 | 1.19 | 1.61 | 2.02 | Upgrade
|
| Other Long-Term Liabilities | 157.3 | 106.24 | 58.82 | - | - | Upgrade
|
| Total Liabilities | 533.7 | 435.99 | 387.11 | 292.12 | 84.75 | Upgrade
|
| Common Stock | 0.52 | 0.52 | 0.52 | 0.51 | 0.51 | Upgrade
|
| Retained Earnings | -3,495 | -3,350 | -3,194 | -2,835 | -2,463 | Upgrade
|
| Treasury Stock | -15.84 | -4.57 | - | - | - | Upgrade
|
| Comprehensive Income & Other | 4,281 | 4,277 | 4,267 | 4,117 | 4,099 | Upgrade
|
| Total Common Equity | 770.63 | 923.18 | 1,073 | 1,283 | 1,637 | Upgrade
|
| Shareholders' Equity | 770.63 | 923.18 | 1,073 | 1,283 | 1,637 | Upgrade
|
| Total Liabilities & Equity | 1,304 | 1,359 | 1,460 | 1,575 | 1,722 | Upgrade
|
| Total Debt | 165.17 | 152.08 | 209.91 | 147.79 | 6.81 | Upgrade
|
| Net Cash (Debt) | 968.51 | 1,022 | 937.93 | 1,151 | 1,531 | Upgrade
|
| Net Cash Growth | -5.28% | 9.01% | -18.50% | -24.82% | -5.32% | Upgrade
|
| Net Cash Per Share | 1.25 | 1.32 | 1.21 | 1.53 | 2.05 | Upgrade
|
| Filing Date Shares Outstanding | 774.92 | 788.82 | 791.76 | 771.46 | 771.46 | Upgrade
|
| Total Common Shares Outstanding | 774.92 | 788.82 | 791.76 | 771.46 | 771.46 | Upgrade
|
| Working Capital | 927.49 | 945.77 | 963.28 | 1,183 | 1,559 | Upgrade
|
| Book Value Per Share | 0.99 | 1.17 | 1.36 | 1.66 | 2.12 | Upgrade
|
| Tangible Book Value | 769.78 | 922.34 | 1,072 | 1,282 | 1,636 | Upgrade
|
| Tangible Book Value Per Share | 0.99 | 1.17 | 1.35 | 1.66 | 2.12 | Upgrade
|
| Machinery | - | 57.83 | 59.38 | 53.3 | 50.03 | Upgrade
|
| Construction In Progress | - | - | - | 27.79 | - | Upgrade
|
| Leasehold Improvements | - | 62.1 | 61.86 | 10.2 | 10.2 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.